



## TransEnterix Named to Deloitte's Technology Fast 500

November 15, 2018

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Nov. 15, 2018-- TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced its naming to Deloitte's 2018 Technology Fast 500™, an annual ranking of the fastest growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors.

"We're thrilled to be recognized as one of Deloitte's 2018 Technology Fast 500 companies," said Todd M. Pope, TransEnterix president and CEO. "TransEnterix's mission is to advance minimally invasive surgical capabilities through digital laparoscopy with the Senhance™ Surgical System. Our growth has come as a result of our ability to deliver on the promise of digital laparoscopy, which provides benefits to patients, surgeons, and hospitals while at the same time meeting the economic constraints of today's value-based healthcare landscape."

The Technology Fast 500 is based on percentage of revenue growth from fiscal year 2014 to 2017. Overall, 2018 Technology Fast 500™ companies achieved revenue growth ranging from 143 percent to 77,260 percent from 2014 to 2017, with median growth of 412 percent.

### About TransEnterix

TransEnterix is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today's value-based healthcare environment. The Company is focused on the commercialization of the Senhance Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics. The Senhance Surgical System is available for sale in the US, the EU and select other countries. For more information, visit [www.transenterix.com](http://www.transenterix.com).

### Forward-Looking Statements

*This press release includes statements relating to the Senhance Surgical System and our current regulatory and commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 8, 2018, and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.*

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181115005282/en/>

Source: TransEnterix, Inc.

#### TransEnterix, Inc.

##### Investor Contact:

Mark Klausner, 443-213-0501

[transenterix@westwiche.com](mailto:transenterix@westwiche.com)

or

##### Media Contact:

Joanna Rice, 951-751-1858

[joanna@greymattermarketing.com](mailto:joanna@greymattermarketing.com)